Neuilly-Sur-Seine

• PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting
  2023-505214-23-00 5 2024-06-07 colon carcinoma
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n … Recruiting
  2023-504637-42-01 6 2023-12-21 aortic valve stenosis
• An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with … Recruiting
  2023-507256-76-00 6 2020-01-14 Ulcerative colitis
• Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota tran … Ended recruitment
  2024-517078-52-00 5 2026-01-19 Patients operated with an IPAA for ulcerative colitis woth active recu
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• BOTAF - Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in pa … Ended recruitment
  2024-513645-37-00 5 2024-09-05 Adult patients with indication for conventional cardiac surgery (CABG,
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended recruitment
  2022-500290-14-01 4 2023-05-11 Colitis ulcerative
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely … Ended recruitment
  2023-504719-34-00 5 2023-02-21 Moderate to Severly Active Ulcerative Colitis
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri … Ended recruitment
  2023-508242-18-00 6 2021-12-21 Crohn's disease
• Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended recruitment
  2023-507974-42-00 4 2021-12-01 Moderate to Severe Ulcerative Colitis
• Hydrocorticose and vasopressin in post-resuscitation syndrome Ended recruitment
  2024-516373-77-00 5 2021-07-18 Adult cardiac arrest patients with sustained ROSC and hemodynamic fail
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M … Ended recruitment
  2023-507188-21-00 5 2021-04-20 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
• The USTAP CD trial USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study Ended recruitment
  2023-503380-42-00 6 2020-11-16 patient with moderate to severe Crohn's disease with at least one acti
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended recruitment
  2023-506994-36-00 5 2018-10-11 Ulcerative Colitis
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended recruitment
  2023-507657-15-00 5 2018-09-13 Ulcerative Colitis
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea … Ended recruitment
  2023-506399-28-00 5 2017-11-08 Crohn's Disease
• PASSPORT Ended
  2023-508584-72-00 5 2024-07-10 Immune Bowel Disease (including Crohn's disease and Ulcerative colitis
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me … Ended
  2022-502372-22-01 4 2023-10-19 Metastatic Breast Cancer HR+, HER2-
• A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjectswith moderate to severe ulcerative colitis Ended
  2022-501263-41-00 4 2023-08-10 Ulcerative Colitis

Showing 25–48 of 54 trials